Pulmonary Valve Replacement for Congenital Heart Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new type of heart valve, the Autus Valve, for children needing pulmonary valve replacement surgery. The valve is unique because it can be adjusted to fit as a child grows through a small balloon procedure. It targets children aged 18 months to 16 years with severe heart issues, such as significant narrowing or leaking of the pulmonary valve. Researchers will frequently monitor participants after receiving the valve to assess its long-term effectiveness. Children with common heart issues requiring a new valve might be suitable candidates for this trial. As an unphased trial, it offers a unique opportunity for children to access innovative treatment that could significantly improve their quality of life.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you have an active infection requiring antibiotics, you must wait 4 weeks after stopping them to participate.
What prior data suggests that the Autus Valve is safe for pediatric patients?
Previous studies have shown promising safety results for the Autus Valve. One study found that the valve functioned well one year after implantation, with no device-related side effects. Another study demonstrated that the valve allowed effective blood flow through the heart six months after the procedure. These findings suggest that patients generally tolerate the Autus Valve well. However, individual experiences can vary, so discussing potential risks with a healthcare provider is important.12345
Why are researchers excited about this trial?
The Autus Valve is unique because it introduces an innovative design for pulmonary valve replacement in individuals with congenital heart disease. Unlike traditional treatments that often rely on bioprosthetic or mechanical valves, the Autus Valve is designed to offer better durability and a more physiological flow pattern, potentially reducing the risk of complications and the need for future interventions. Researchers are excited about this treatment because it aims to improve the quality of life for patients by enhancing valve performance and longevity, which could lead to fewer surgeries over a patient's lifetime.
What evidence suggests that the Autus Valve is effective for pulmonary valve replacement in congenital heart disease?
Research has shown that the Autus Valve, which participants in this trial will receive, holds promise for children needing a new pulmonary valve. One study found that the valve functioned well and had no issues one year after implantation. Designed to grow with the child, the valve can be adjusted as the child grows, ensuring proper blood flow over time. Early results suggest the valve performs effectively without causing problems. Overall, the Autus Valve appears to be a safe and effective option for treating heart problems in young patients.23567
Are You a Good Fit for This Trial?
This trial is for children aged 18 months to 16 years with certain types of congenital heart disease who need surgical pulmonary valve replacement. Participants must be able to attend follow-up visits and have a body size suitable for the Autus Valve. Some medical conditions, active infections, or other risk factors may prevent participation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-Implant Evaluation
Subjects are evaluated prior to the Autus Valve implant procedure
Treatment
Autus Valve implantation and immediate post-implantation evaluation
Post-Implant Monitoring
Subjects are monitored at hospital discharge, 30 days, and 6 months post-implantation
Long-term Follow-up
Annual evaluations through 10 years post-valve implantation
What Are the Treatments Tested in This Trial?
Interventions
- Autus Valve
Trial Overview
The study tests the Autus Size-Adjustable Valve in kids needing pulmonary valve replacement surgery. The valve can be expanded during and after surgery as the child grows. All participants receive this device and are followed up regularly for up to 10 years.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Pulmonary Valve Replacement Surgery with the Autus Valve
Find a Clinic Near You
Who Is Running the Clinical Trial?
Autus Valve Technologies, Inc.
Lead Sponsor
Edwards Lifesciences
Lead Sponsor
Todd Brinton
Edwards Lifesciences
Chief Medical Officer since 2023
MD from Stanford University
Bernard Zovighian
Edwards Lifesciences
Chief Executive Officer since 2023
MBA from INSEAD
Citations
Novel size-adjustable pulmonary valve US early feasibility ...
... effectiveness data throughout the study ... Outcome and performance of bioprosthetic pulmonary valve replacement in patients with congenital heart disease.
NCT05006404 | Autus Valve Pivotal Study
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to ...
Novel Size-Adjustable Pulmonary Valve U.S. Early ...
One-year results of the novel Autus Size-Adjustable Valve EFS demonstrated intact valve function and no device-related adverse events.
Autus Valve Pivotal Study
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 ...
72345 | Novel Size-Adjustable Pulmonary Valve U.S. Early ...
In this feasibility study evaluating the novel Autus Size-Adjustable Valve, one-year results demonstrated intact valve function and no device-related adverse ...
NCT07466745 | Autus Valve Continued Access Study (CAS)
Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, ...
Autus Valve Pivotal Study | Clinical Research Trial Listing
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.